Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 12, 2026

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

Biomarkers in bladder cancer.

Ian Proctor1, Kai Stoeber, Gareth H Williams

  • 1Research Department of Pathology and UCL Cancer Institute, The Paul O'Gorman Building, University College London, Gower Street, London, UK.

Histopathology
|June 29, 2010
PubMed
Summary

Discovering new bladder cancer biomarkers can improve early diagnosis and treatment. This review explores current biomarker development, challenges in clinical translation, and a novel approach using DNA replication licensing machinery.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evolutionary characterization of lung cancer metastasis.

Nature·2026
Same author

Non-Secretory Myeloma With Non-Producing Phenotype Presented as Plasma Cell Leukaemia With Plasmablast Morphology.

EJHaem·2026
Same author

Diagnosis and management of acute erythroid leukemia (AEL).

Leukemia & lymphoma·2025
Same author

Dissecting CD47 expression in lymphoid neoplasms to inform precision immunotherapy with anti-CD47 phagocytic checkpoint blockade.

Haematologica·2025
Same author

Dermatology response to the Hyperinflammation and HLH Across Specialty Collaboration consensus guideline - Authors' reply.

The Lancet. Rheumatology·2024
Same author

Cell-cycle phase progression analysis identifies three unique phenotypes in soft tissue sarcoma.

BMC cancer·2024

Area of Science:

  • Oncology
  • Biomarker Discovery
  • Molecular Diagnostics

Background:

  • Cancer biomarkers aid in early tumor diagnosis, risk assessment, and treatment prediction.
  • Bladder cancer diagnosis relies on subjective and expensive methods like cystoscopy, cytology, and histology.
  • Current methods offer limited insight into tumor molecular characteristics.

Purpose of the Study:

  • To review the current state of bladder cancer biomarker development.
  • To examine challenges hindering the clinical translation of identified biomarkers.
  • To introduce a novel biomarker development approach utilizing DNA replication licensing machinery.

Main Methods:

  • Review of hypothesis-driven (protein-focused) and genomics-based biomarker discovery approaches.

More Related Videos

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

Cell-Free DNA Integrity Analysis in Urine Samples
07:58

Cell-Free DNA Integrity Analysis in Urine Samples

Published on: January 5, 2017

Related Experiment Videos

Last Updated: Jun 12, 2026

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

Cell-Free DNA Integrity Analysis in Urine Samples
07:58

Cell-Free DNA Integrity Analysis in Urine Samples

Published on: January 5, 2017

  • Analysis of factors limiting successful clinical implementation of biomarkers.
  • Introduction of a new strategy based on DNA replication licensing machinery.

    • Main Results:

    • Numerous diagnostic and prognostic bladder cancer biomarkers have been identified.
    • Few identified biomarkers have successfully transitioned into clinical practice.
    • A novel approach using DNA replication licensing machinery is proposed.

    Conclusions:

    • Improved bladder cancer diagnostics and prognostics are needed.
    • Overcoming barriers to clinical translation is crucial for biomarker utility.
    • Novel approaches, such as those involving DNA replication licensing, hold promise for future biomarker development.